Lana Lange, MD
Obstetrics & Gynecology · Cincinnati, OHNPI 1497944821
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,690 of the $4,174 with a category attached, or 88.4%. Gilead accounts for 92.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $4,099 and has fallen 99.9% since, to $6 in 2025.
Across 18 payments — averaging $231.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$4K
- Minerva Surgical, Inc$134
- Astellas Pharma US Inc$41
- Organon$29
- Therapeuticsmd, Inc.$25
- Roche Diagnostics Corporation$23
- plus $75 from 6 others
What the payments were for
- Consulting fees$3,69088%
- Food & beverage$48412%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 4 | $3,848 |
| Minerva Surgical, Inc | 2 | $134 |
| Astellas Pharma US Inc | 2 | $41 |
| Organon | 1 | $29 |
| Therapeuticsmd, Inc. | 2 | $25 |
| Roche Diagnostics Corporation | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Exeltis, USA Inc. | 1 | $15 |
| Avion Pharmaceuticals | 1 | $11 |
| Duchesnay USA Incorporated | 1 | $11 |
| Merck | 1 | $11 |
| Meditrina | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,174 in reported general payments places this provider in the 85th percentile of 1,376 obstetrics & gynecology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 58 | $2,006 |
| ValacyclovirValacyclovir Hcl | 24 | $792 |
| ProgesteroneProgesterone, Micronized | 16 | $410 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 14 | $314 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 12 | $187 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $162 |
| Fluconazole | 17 | $130 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Cincinnati
- David SchwartzCincinnati$169K
- Gerard ReillyCincinnati$74K
- Michael KarramCincinnati$47K
- Sunbal JavaidCincinnati$32K
- James SosnowskiCincinnati$31K
- Gretchen FermannCincinnati$31K
- Rocco RossiCincinnati$18K
- Meredith PensakCincinnati$14K
- David DhanrajCincinnati$12K
- David SheynCincinnati$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.